Official Title Laying the Groundwork for Personalized Medicine in Aphasia Therapy: Genetic and Cognitive Predictors of Restorative Treatment Response

Purpose

This NIH-funded project will investigate patient-specific factors that may influence response to therapy for language impairment after stroke, or aphasia. Results from this work will assist with better estimation of prognosis for stroke survivors with aphasia, which could empower patients and families to make more informed health care decisions about how to pursue the most appropriate rehabilitation services based on their unique characteristics, such as genetics, cognitive skills, and brain structure after stroke.

Could this study be right for you?

Participants must meet the following criteria:

• Native English speaker
• Able to have an MRI

Age Range

18 and up

Official Title A Randomized, Double-Blind, Double-Dummy, Active-Controlled Study Comparing the Efficacy, Safety and Tolerability of ABBV-951 to Oral Carbidopa/Levodopa in Advanced Parkinson's Disease Patients

Purpose

The purpose of this study is to find out how well ABBV-951 works to control Parkinson's disease symptoms compared to oral Carbidopa (CD)/Levodopa (LD). The study is also seeking to test whether ABBV-951 is well tolerated in patients with Parkinson's disease.

Could this study be right for you?

1. Male or female, age 30 or older
2. Has not received deep brain stimulation, Carbidopa (CD)/Levodopa (LD) enteral suspension, or any other Parkinson's Disease (PD) medication as continuous daily infusion
3. Subject does not have a history of significant skin conditions or disorders
4. Subject does not have a recent (within 6 months before screening) history of drug or alcohol abuse
5. Subject does not have a history or presence of psychotic episodes
6. Subject does not have other clinically significant unstable medical conditions
7. Subject must have a diagnosis of levodopa-responsive idiopathic PD

* other eligibility criteria to be discussed/reviewed with the study team

Age Range

30 and up

Official Title A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)

Purpose

Hand-Foot Skin Reaction (HFSR) is a common adverse event induced by Vascular Endothelial Growth Receptor Inhibitor (VEGFRi) treatment in cancer patients. The main purpose of this study is to evaluate the safety and efficacy of OQL011 compared to vehicle ointment in treating patients with moderate to severe VEGFRi-associated HFSR. This study will also identify an optimal dosage for Phase III study and explore the pharmacokinetics profile of OQL011 in HFSR patients.

Could this study be right for you?

• Patient must be age 18 years of age or older.
• Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week.
• Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage.

Age Range

18 and up

Official Title A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Operationally Seamless, Adaptive Phase 2/3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients with Severe or Very Severe Alopecia Areata (JAHO)

Purpose

The main reason for you to take part in this study is not to treat you for your condition but to help in answering the following research questions:
• Whether baricitinib is better than placebo in the treatment of patients with severe alopecia areata (AA)
• The safety of baricitinib and any side effects you may have when you take it.

Could this study be right for you?

• Are at least 18 years and ≤60 years for males (≤70 years of age for females) at the time of informed consent
• Are able to read, understand, and give documented (electronic or paper signature) informed consent
• Current AA episode of more than 6 months’ duration and hair loss encompassing ≥50% of the scalp
• No spontaneous improvement over the past 6 months

Age Range

18 and up

Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of Adults with Major Depressive Disorder

Purpose

Brexpiprazole is a medication being studied as a possible treatment for adjunctive treatment for Major Depressive Disorder (MDD). The reason for this study is to find out about the potential benefits and safety of Brexpiprazole.

Could this study be right for you?

Inclusion criteria:

• Between the ages of 18 and 65
• Currently depressed
• Currently taking an antidepressant
• Have tried at least 2 antidepressant medications

Age Range

18 and up

Official Title A Randomized Trial of Continuous Positive Airway Pressure (CPAP) for Sleep Apnea in Pregnancy (SLEEP)

Purpose

The purpose of this study is to understand how Continuous Positive Airway Pressure (CPAP)
for mild to moderate sleep apnea may affect hypertensive disorders of pregnancy and other
complications of pregnancy such as gestational diabetes.

Could this study be right for you?

1. No prior delivery at or after 20 weeks 0 days of gestation
2. Pregnancy with only one fetus
3. Gestational age at randomization between 14 weeks 0 days and 21 weeks 6 days
4. Diagnosis with mild to moderate OSA as defined by an AHI score ≥ 5 and <30

Age Range

18 and up

Official Title The influence of receiving real-time visual feedback on breathing during treadmill running to exhaustion

Purpose

The purpose of this research is to assess if receiving real-time visual feedback on your breathing pattern during a run has any influence on time to exhaustion.

The feedback will be provided through animations on a screen placed in front of the treadmill that open and close as the chest and abdomen expand and contract. Research has shown that you want the chest and abdomen to expand and contract at the same time to achieve the most efficient breathing possible, meaning you will want the animations to open and close at the same time.

The ultimate objective is to see if this feedback allowed the participant to last longer until reaching their exhaustion point.

Could this study be right for you?

• Healthy adults who run 5 to 20 miles per week
• Have NOT been injured while running in the past six months
• Have NOT been medically diagnosed with breathing deficiencies
• must be age 18 or older

Those who are interested in participating will be directed to complete a survey, found at go.osu.edu/RunningAndBreathing, to ensure that they meet the previously mentioned criteria.

Age Range

18 and up

Official Title Relationship Dynamics in Families of Children with ADHD and Their Opposite-Sex Siblings

Purpose

This study is being done to better understand relationship dynamics between children with ADHD, their siblings, and their parents. Our goal is to better understand how differences in family dynamics affect children with ADHD. Participants will be asked to fill out several self-report questionnaires and engage in a family conflict task. During several tasks, participants will have various physiological measures (e.g., heart rate, breathing rate, etc.) taken using electrodes placed on their body. Results of this study will be used to develop other studies and to inform future treatment and prevention programs.

Could this study be right for you?

We are recruiting children between 8 and 10 years old with an opposite sex sibling. In order to participate, families must meet the following criteria:

• Mothers must be willing to participate
• They must have a child between ages 8 and 10
• That child must have a sibling of the opposite sex that is within 2 years of their age

Age Range

6 and up

Official Title Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD (TERPSIS)

Purpose

To evaluate the efficacy and safety of study drug NBI-1065846, used as adjunctive treatment to oral antidepressant medication(s), compared with a placebo when treating symptoms of anhedonia.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosis of MDD
• Currently on stable dose of at least one antidepressant
• Experiencing anhedonia (low interest, decreased enjoyment)

Age Range

18 and up

Official Title Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of a Plant Polyphenol for COVID-19

Purpose

The purpose of this trial is to determine whether a commercially available dietary supplement may decrease the severity of patients with early COVID-19

Could this study be right for you?

Inclusion Criteria:

• Outpatients who test positive for infection with SARS-CoV-2
• Age 45 years and older
• Experiencing COVID 19 symptoms for 7 days or less, OR 72 hours of new respiratory symptoms
• Patient must have access to the internet or a smartphone to complete surveys
• English-speaking patients

Age Range

45 and up

Official Title Safety of REL-1017 for Major Depressive Disorder (RELIANCE-OLS)

Purpose

This is a 1-year open-label study to access the safety of REL-1017, a study medication, once daily as a workable treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug for the duration of the treatment period.

This study will last 13 months and you will come to the study site at least 15 times over this period. This will include 1 final visit about 1 month after you stop taking the study drug.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with Major Depressive Disorder (MDD)
• Currently depressed
• Taking or having taken between 1 and 3 antidepressants for the current episode of depression

Age Range

18 and up

Official Title Microdosed Atropine for the Reduction of Pediatric Myopia Progression (The CHAPERONE Study)

Purpose

The purpose of this study to test the safety and effectiveness of atropine 0.1% and atropine 0.01% eye solutions. These drugs are being tested to see if they slow the worsening of nearsightedness. Children who participate in this study will be asked to use their assigned study medication every night and willing to attend visits at The Ohio State University of Optometry 1 month after starting treatment. These visits will continue for 6 months until the duration of the study ends. This study will take place over a 4-year time period.

Could this study be right for you?

• Children aged 3 to < 13 years old.
• No previous use of medications related to myopia control.
• Glasses and/or contact lens prescription between -1.00 and -6.00 diopters.

Interested guardians who believe their child may be eligible should contact study coordinators to further determine eligibility.

Age Range

3 and up